Clinical trial · Interventional
Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer
Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer (ASPIRE)
NCT04235179CI-TRIAL-00042913ASPIREunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 30 Gy in 5 fractions, once weekly to the pelvis in post operative patients with endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SABR | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SABR
- description
- Pelvic SABR for post-op endometrial cancer
- interventionNames
- Radiation: SABR
Primary outcomes (1)
- measure
- Acute Treatment-Related Adverse Events
- timeFrame
- 3 months after accrual is completed
- description
- The number of participants with acute (\<3 months) urinary and bowel treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) criteria
Secondary outcomes (3)
- measure
- Late Treatment-Related Adverse Events
- timeFrame
- 5 years after accrual is completed
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with histologically confirmed endometrial adenocarcinoma * Patient is a candidate for adjuvant pelvic radiation (+/- vault brachytherapy), meeting one of the following conditions: High grade histology OR Outer-half myometrial invasion with any risk factors OR FIGO stage II - IIIC1. * Age ≥18 years. * Patients who are to receive adjuvant systemic therapy in addition to pelvic radiotherapy will be eligible provided that there is at minimum a 3-week interval between any radiation treatment and chemotherapy treatments. Exclusion Criteria: * Patient has had prior pelvic radiotherapy. * Patient has Type II endometrial cancer histology (ie. Serous, clear cell or carcinosarcoma). * Patient has a contraindication to pelvic radiotherapy, such as but not limited to a connective tissue disease or inflammatory bowel disease. * Patient has a contraindication to CT contrast. * Patient has a hip prosthesis.
References
Publications (0)
Data not yet available
No reference posted for this study.